Mallinckrodt PLC (NYSE:MNK) has been given a consensus rating of “Hold” by the twenty-two ratings firms that are covering the stock, Marketbeat reports. Three equities research analysts have rated the stock with a sell recommendation, twelve have given a hold recommendation and seven have given a buy recommendation to the company. The average twelve-month target price among brokers that have issued a report on the stock in the last year is $39.52.
Several research firms have issued reports on MNK. Barclays cut shares of Mallinckrodt from an “equal weight” rating to an “underweight” rating and lowered their price objective for the company from $23.00 to $20.00 in a research report on Friday, February 2nd. ValuEngine cut shares of Mallinckrodt from a “buy” rating to a “hold” rating in a research report on Friday, February 2nd. Zacks Investment Research raised shares of Mallinckrodt from a “strong sell” rating to a “hold” rating in a research report on Tuesday, January 9th. Mizuho reissued a “neutral” rating and issued a $21.00 price objective (down from $22.00) on shares of Mallinckrodt in a research report on Tuesday, January 9th. Finally, Cantor Fitzgerald set a $42.00 price objective on shares of Mallinckrodt and gave the company a “buy” rating in a research report on Monday, January 8th.
Mallinckrodt (NYSE:MNK) traded up $0.06 during trading on Wednesday, reaching $16.80. 2,212,900 shares of the company’s stock traded hands, compared to its average volume of 2,904,479. The stock has a market cap of $1,600.00, a PE ratio of -840.00, a price-to-earnings-growth ratio of 0.32 and a beta of 1.04. The company has a debt-to-equity ratio of 1.08, a quick ratio of 1.05 and a current ratio of 1.38. Mallinckrodt has a 12 month low of $15.27 and a 12 month high of $55.32.
Hedge funds and other institutional investors have recently bought and sold shares of the stock. State of Alaska Department of Revenue bought a new position in shares of Mallinckrodt during the 4th quarter worth approximately $129,000. Amundi Pioneer Asset Management Inc. bought a new position in shares of Mallinckrodt during the 4th quarter worth approximately $190,000. Sterling Capital Management LLC bought a new position in shares of Mallinckrodt during the 2nd quarter worth approximately $204,000. Shelton Capital Management bought a new position in shares of Mallinckrodt during the 3rd quarter worth approximately $205,000. Finally, Sciencast Management LP bought a new position in shares of Mallinckrodt during the 4th quarter worth approximately $210,000. Hedge funds and other institutional investors own 97.38% of the company’s stock.
TRADEMARK VIOLATION WARNING: “Analysts Set Mallinckrodt PLC (MNK) Price Target at $39.52” was first posted by Week Herald and is the property of of Week Herald. If you are reading this article on another website, it was stolen and reposted in violation of U.S. and international copyright & trademark legislation. The legal version of this article can be accessed at https://weekherald.com/2018/03/14/analysts-set-mallinckrodt-plc-mnk-price-target-at-39-52.html.
Mallinckrodt Company Profile
Mallinckrodt public limited company develops, manufactures, markets and distributes branded and generic specialty pharmaceutical products and therapies. The Company focuses on various therapeutic areas, such as autoimmune and rare disease specialty areas, including neurology, rheumatology, nephrology, ophthalmology and pulmonology; immunotherapy and neonatal critical care respiratory therapies; analgesics and hemostasis products, and central nervous system drugs.
Receive News & Ratings for Mallinckrodt Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mallinckrodt and related companies with MarketBeat.com's FREE daily email newsletter.